Effect of Metformin in Diabetic Patients After Treatment of Intracranial Aneurysm: A Nationwide Cohort Study
Abstract
BACKGROUND: Intracranial aneurysm (IA) is the most common cause of subarachnoid hemorrhage (SAH), causing high morbidity and mortality. Experimental data have shown that metformin, an antidiabetic agent, has protective effects against IA rupture. This study assessed the effect of metformin on the long-term prognosis of diabetic patients treated for IA.
METHODS: This retrospective cohort study included diabetic patients who underwent surgical clipping or endovascular coiling for IA between January 2009 and December 2020, based on Korean health insurance claims data. The primary outcome was the development of SAH. The risk associated with metformin use was evaluated using a multivariable Cox proportional hazards model supplemented with subgroup, propensity score matching, and time-varying Cox regression analyses.
RESULTS: Of 14,086 diabetic patients treated for IA, 9,612 (68.2%) were metformin users. During a mean follow-up of 4.6 years, 120 (0.9%) patients experienced SAH. Metformin use was associated with a reduced risk of SAH (adjusted hazards ratio, 0.63; 95% confidence interval, 0.41-0.95; P = 0.028). This finding was consistent in subgroup, propensity score matching, and time-varying Cox regression analyses.
CONCLUSION: Metformin use in diabetic patients treated with clipping or coiling for IA was associated with reduced risk of SAH. These findings support the use of metformin as the preferred antidiabetic agent for such patients considering these benefits.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 14,086 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.